Emyria expands MDMA programs following landmark TGA decision

Australia's TGA to designate MDMA and psilocybin Schedule 8 “Controlled Medicines” from July 1st 2023, facilitating access to patients via appropriately qualified Authorised Prescribers [1]

Emyria uniquely positioned to advance and help commercialise MDMA-assisted therapies via:

• Emyria’s established clinical & data infrastructure - can support qualified Authorised Prescribers and therapists deliver MDMA-assisted therapy safely and at-scale
• Real-World Data generation during treatment - can inform care model innovation, drug registration programs, and advance Emyria’s novel, advanced MDMA-inspired drug discovery program with partner the University of Western Australia

A short deck summarising Emyria’s updated strategy accompanies this announcement